UBS Group AG increased its holdings in Jiangsu Hengrui Pharmaceuticals (01276) by 1,117,000 shares at approximately HK$49.86 per share.
On October 28, UBS Group AG increased its holdings in Hengrui Pharmaceuticals (01276) by 1,117,000 shares at HK$49.8626 per share, for a total amount of approximately HK$55.6965 million.
The latest data from the Hong Kong Stock Exchange shows that on October 28, UBS Group AG increased its holdings in Jiangsu Hengrui Pharmaceuticals (01276) by 1,117,000 shares at HK$49.8626 per share, for a total amount of approximately HK$55.6965 million. After the increase, its latest holding is approximately 13,457,400 shares, with a latest shareholding ratio of 5.21%.
Related Articles
Peet's Coffee parent company reports first full quarter with consolidated results: Keurig Dr Pepper (KDP.US) Q3 results beat expectations, coffee business spin-off countdown begins
TIME INTERCON (01729) grants 13.4 million share options
EPIWORLD (02726) repurchased 17,300 shares for HK$1.3245 million on November 3.
Peet's Coffee parent company reports first full quarter with consolidated results: Keurig Dr Pepper (KDP.US) Q3 results beat expectations, coffee business spin-off countdown begins
TIME INTERCON (01729) grants 13.4 million share options
EPIWORLD (02726) repurchased 17,300 shares for HK$1.3245 million on November 3.
